ERBB2 and breast cancer: LY3039478, tested in heavily pretreated patients with advanced or metastatic cancer, caused partial response (PR) in one case of breast cancer (Estrogen/Progesterone receptor+, HER2-, FBXW7 mutated) and SD in around one-third of patients receiving different GSI dose regimens.